Navigation Links
Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured''

evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA-approved regimen for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C, with major studies initiated to advance treatment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and patients who have failed to respond to previous therapy.

Important Safety Information about PEGASYS

What is PEGASYS?

PEGASYS is a medicine used to treat some adults who have hepatitis C or hepatitis B and signs of liver damage. PEGASYS works to reduce the amount of virus in your blood, helping your body fight the virus.

PEGASYS (Peginterferon alfa-2a), like other alpha interferons, can cause fatal or make life-threatening problems worse (like mental, immune system, heart, liver, lung, intestinal and infections). Your doctor should monitor you during regular visits. If you show signs or symptoms of these conditions, your doctor may stop your medication. In most patients, these conditions get better after you stop taking PEGASYS (see medication guide for more information and warnings).

What is COPEGUS?

COPEGUS is a medicine that works by s
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:3/27/2015)... The Temple Health & Bioscience District (THBD) today ... at 1802 South First St. in the Temple Medical and ... City of Temple to receive funding for ... Texas Veterans Health Care System, the new facility will enable ... biotechnology and life science companies. ...
(Date:3/27/2015)... March 27, 2015 XRpro Sciences, Inc., ... discovery and development services which features high throughput ... industry, announced financial results for the year ended ...  Tyson, Chairman of XRpro Sciences commented, "We have ... from development stage to commercial stage in large ...
(Date:3/27/2015)... 2015 As of February, InControl Medical, ... for women. "Shipping thousands of our ... is the hundreds of letters, emails and phone ... been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution for ...
Breaking Medicine Technology:Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2
... Life Sciences Holdings, Inc. (OTC Bulletin ... in the discovery, development and commercialization of novel drugs ... diseases, announced today that Dawson James Securities Inc., has ... report highlights Restanza™ (cethromycin) as a promising late-stage antibacterial ...
... 2010 HealthLeaders-InterStudy, a leading provider of managed ... a shift toward coordinated patient care in Portland, ... to the Portland, Maine Market Overview, ... coordinated care models such as patient-centered medical homes ...
Cached Medicine Technology:Dawson James Initiates Research Coverage of Advanced Life Sciences 2Dawson James Initiates Research Coverage of Advanced Life Sciences 3Consolidated Portland, Maine Healthcare Market Will Hamper Pharmaceutical Reps' Access to Physicians 2
(Date:3/28/2015)... (PRWEB) March 28, 2015 Healthpointe’s otolaryngologists, ... nose and throat disorders, are now offering a ... common issue which is characterized by the presence of ... in 5 people, tinnitus is a prevalent symptom that ... while it is non-fatal, tinnitus can impede a person’s ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s Wellness Celebration on ... Center in Chesapeake, Virginia. Each year, ARDX celebrates Women’s ... the Hampton Roads region. The 2015 Women’s History Month ... grow stronger through sharing their stories and learning the strategies ... theme is T-talk where we will share a cup of ...
(Date:3/28/2015)... LTW Cyber is an innovation hub for technology ... of addressing the needs of the global market for ... to grow while seeking collaborative opportunities with the other ... in LTW Cyber focus on secure application security, grounded ... and analyzing open source. As the hub matures, ...
(Date:3/27/2015)... March 27, 2015 In her mid-forties and ... her from working, Monica K. arrived at JET Uniform ... department quiet, defensive and scared. The owners and staff at ... Services (EPSS) to offer jobs to challenged residents like ... and a willingness to begin with the end in mind,” ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 First Choice ... today. The new facility is located 12665 W Lake Houston ... a resident of Summerwood, I look forward to delivering the ... Dr. Sowell, Facility Medical Director of First Choice Emergency Room ... Emergency Room made a donation to Summer Creek High School ...
Breaking Medicine News(10 mins):Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Canadian Cybersecurity Ventures Globalize as a Collective 2Health News:Canadian Cybersecurity Ventures Globalize as a Collective 3Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2
... New Component Streamlines Safe ... ... PhaSeal System for the safe handling of hazardous drugs, now offers the Secondary Set (C60) for ... ease of use, the non-vented Secondary Set offers the following features:, , , ...
... Nov.1 issue of the journal Sleep shows that ... of sleep disturbances. Findings suggest that this general improvement in ... demands and stress rather than from actual health benefits of ... sleep in the seven years after retirement were 26 percent ...
... Previous studies have shown that hepatitis C virus ... Americans than in whites. However, researchers demonstrate in this ... of the American Association for the Study of Liver ... that recurrent HCV in the transplanted liver progresses faster ...
... at increased risk of deatheven compared to patients at ... research being presented at the American Society of Nephrology,s ... "Our study indicates that body fat may be ... at Harbor-UCLA). "The results add to the increasing number ...
... found that hepatitis B does not increase the risk for pancreatic ... The results contradict a previous study in 2008 that suggested ... B is an inflammation of the liver caused by a viral ... for the Study of Liver Diseases, Annual Meeting in Boston. ...
... House speaker Nancy Pelosi is scheduled to speak about ... growing coalition of community groups and healthcare partners that are ... can cause liver cancer and damage, or if untreated, death. ... & Toland is a part, promotes hepatitis B screening, vaccination ...
Cached Medicine News:Health News:Carmel Pharma Introduces PhaSeal Secondary Set (C60) 2Health News:Study shows that sleep disturbances improve after retirement 2Health News:African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C 2Health News:African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C 3Health News:For dialysis patients, skinny is dangerous 2Health News:Brown & Toland Supports Fight Against Hepatitis B 2
... has created this extremely versatile and efficient ... liquid handling. With EDOS, high sample throughput ... with ease. ,The smallest volume that ... corresponding Combitip. The easy-to-follow user menus presented ...
... Dilutor-Dispenser is designed to transfer ... the clinical, biological, and chemical ... and performance as Gilsons other ... is ideal for routine laboratory ...
... synQUAD technology is a patented non-contact dispensing ... with a microsolenoid valve and stage stepper ... of liquid onto various slides, plates, or ... well, coefficient of variation (CVs) are less ...
16 channel Parallel dispenser using Positive Air Displacement Technology...
Medicine Products: